^
No biomarker
Mucosal Melanoma
toripalimab
Sensitive: B - Late Trials
No biomarker
Mucosal Melanoma
ALKS 4230
Sensitive: B - Late Trials
PD-L1 expression
Mucosal Melanoma
toripalimab
Sensitive: C2 – Inclusion Criteria
BRAF mutation
Mucosal Melanoma
PD1 inhibitor
Sensitive: C3 – Early Trials
KIT mutation
Mucosal Melanoma
PD1 inhibitor
Sensitive: C3 – Early Trials
MDM2 amplification
Mucosal Melanoma
ipilimumab
Resistant: C3 – Early Trials
MDM4 amplification
Mucosal Melanoma
ipilimumab
Resistant: C3 – Early Trials
MDM2 amplification
Mucosal Melanoma
nivolumab + ipilimumab
Resistant: C3 – Early Trials
MDM2 amplification
Mucosal Melanoma
nivolumab
Resistant: C3 – Early Trials
MDM4 amplification
Mucosal Melanoma
nivolumab + ipilimumab
Resistant: C3 – Early Trials
MDM4 amplification
Mucosal Melanoma
nivolumab
Resistant: C3 – Early Trials
EGFR amplification
Mucosal Melanoma
ipilimumab
Resistant: C3 – Early Trials
EGFR amplification
Mucosal Melanoma
nivolumab
Resistant: C3 – Early Trials
EGFR amplification
Mucosal Melanoma
nivolumab + ipilimumab
Resistant: C3 – Early Trials
EGFR amplification
Mucosal Melanoma
pembrolizumab
Resistant: C3 – Early Trials
MDM4 amplification
Mucosal Melanoma
pembrolizumab
Resistant: C3 – Early Trials
MDM2 amplification
Mucosal Melanoma
pembrolizumab
Resistant: C3 – Early Trials
NRAS mutation
Mucosal Melanoma
PD1 inhibitor
Resistant: C3 – Early Trials
BRAF mutation
Mucosal Melanoma
cisplatin + dacarbazine
Sensitive: C3 – Early Trials
NRAS mutation
Mucosal Melanoma
cisplatin + temozolomide
Sensitive: C3 – Early Trials
KIT mutation
Mucosal Melanoma
cisplatin + temozolomide
Sensitive: C3 – Early Trials
BRAF mutation
Mucosal Melanoma
cisplatin + temozolomide
Sensitive: C3 – Early Trials
NRAS mutation
Mucosal Melanoma
cisplatin + dacarbazine
Sensitive: C3 – Early Trials
KIT mutation
Mucosal Melanoma
cisplatin + dacarbazine
Sensitive: C3 – Early Trials
KIT L576P
Mucosal Melanoma
sorafenib
Resistant: C4 – Case Studies
KIT L576P
Mucosal Melanoma
temsirolimus
Resistant: C4 – Case Studies
KIT L576P
Mucosal Melanoma
imatinib
Resistant: C4 – Case Studies